Thomas Langenickel

Company: Ethris

Job title: Chief Medical Officer

Seminars:

Safety, Tolerability, Pharmacokinetics & Target Engagement of ETH47 in Healthy Subjects 8:00 am

Showcasing nasal administration of ETH47 development for the prevention of virusdriven exacerbation in patients with asthma Demonstrating data on safety and well tolerated and not systemically bioavailable in healthy trial participants Overall, results present a dose-dependent local target protein inductionRead more

day: Day 2 AM